WO2015114176A1 - Produit cosmétique à propriétés contre le vieillissement de la peau - Google Patents

Produit cosmétique à propriétés contre le vieillissement de la peau Download PDF

Info

Publication number
WO2015114176A1
WO2015114176A1 PCT/ES2014/070068 ES2014070068W WO2015114176A1 WO 2015114176 A1 WO2015114176 A1 WO 2015114176A1 ES 2014070068 W ES2014070068 W ES 2014070068W WO 2015114176 A1 WO2015114176 A1 WO 2015114176A1
Authority
WO
WIPO (PCT)
Prior art keywords
percentage
liposomes
cosmetic product
skin
properties
Prior art date
Application number
PCT/ES2014/070068
Other languages
English (en)
Spanish (es)
Inventor
Gabriel SERRANO SANMIGUEL
Juan Manuel SERRANO NUÑEZ
Ana TORRENS TOMAS
Original Assignee
Dermopartners, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermopartners, S.L. filed Critical Dermopartners, S.L.
Priority to PCT/ES2014/070068 priority Critical patent/WO2015114176A1/fr
Publication of WO2015114176A1 publication Critical patent/WO2015114176A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a cosmetic product that has properties to combat skin aging and that has its application in the field of beauty, cosmetics and dermatology centers.
  • the invention claimed is a new cosmetic preparation against skin aging that has a series of active ingredients, of which the most relevant are trepenone, tripeptide-32 and L-glutamyl amidoethyl imidazole, in addition to others such as hyaluronic acid, adenosine, phytosphingosine, lysate of bifidobacteria and ascorbyl palmitate or retinol palmitate and some of them are liposomes.
  • active ingredients of which the most relevant are trepenone, tripeptide-32 and L-glutamyl amidoethyl imidazole, in addition to others such as hyaluronic acid, adenosine, phytosphingosine, lysate of bifidobacteria and ascorbyl palmitate or retinol palmitate and some of them are liposomes.
  • trepenone tripeptide-32 and L-glutamyl amidoethyl imid
  • a complete anti-aging treatment should provide a youthful appearance to the face:
  • the cosmetic product described here consists of a series of active ingredients that decrease the number of cells that enter the senescence phase while promoting the repair of skin cell DNA.
  • active ingredients and adjuvants found in the composition of the product object of the patent are the following:
  • Each of these active ingredients has properties that contribute to the product having these properties to combat skin aging and are indicated below:
  • GGA Geranil geranone active against senescence
  • Geranylgeranyl isoprene is a key molecule in cellular functioning, both at the level of membrane receptors, and in the functionality of intracellular proteins and their signaling.
  • the telomere is a repeated sequence of nucleotides that terminates the chromosomes and is partially bent over their end to protect it.
  • the chromosomes are detangled, duplicated and then recompacted.
  • the telomere reaches a short critical length, due to its progressive erosion after each replication, the cells enter senescence.
  • Telomeres can also be damaged by UV radiation and exogenous molecules.
  • the properties of the active substance tripeptide-32 are: ⁇ It is a "CLOCK GEN ACTIVATOR", that is, an ingredient that activates one or more biological clock genes present in keratinocytes to produce proteins that repair DNA damage.
  • DNA repair enzyme an enzyme that is able to function to repair DNA damage.
  • ⁇ Enzyme capable of "Repairing” means, with respect to the skin, that the viability of keratinocytes, strength and longevity were generally improved.
  • Tripeptide-32 is an activator of the CLOCK and PER1 genes which in turn are activators of keratinocytes. Activation of these genes promotes cell viability, cell longevity, inhibition of cell damage due to environmental aggressions, and repair by healthy keratinocytes of DNA damage.
  • Glutamyl Amidoethyl Imidazole GAEI is a pseudopeptide derived from histamine that restores and stimulates the skin's natural defense system and cellular metabolism, in a mechanism of action similar to cytokines. It produces in the skin an optimization of the activity of Vitamin D and microcirculation, a resynchronization of circadian rhythms and a stimulation of circadian genes.
  • Ceramides are fatty amides of sphingosine or phytosphingosine. They are located in the stratum corneum of the skin and form a substantial part of the lipid barrier of human skin, which is responsible for the aggressions of the external environment and to maintain the balance of hydration necessary for its good conservation.
  • - Filagrin is a protein synthesized in the epidermis of the granular stratum. It has a key role in the keratinization process:
  • NMF natural moisturizing factor
  • Bifidobacteria lysate It is a type of digestive bacteria, which can prevent damage induced by UV radiation in the epidermis and dermis, stimulating the enzymatic repair of the endogenous cellular system.
  • a liposome cosmetic product which has different cosmetic forms such as solution, serum, emulsion, suspension, etc. in which the different components can be found in the case of nourishing cream in the following proportions of active ingredient and liposomes:
  • CERAMIDE EOP ⁇ 0.01 in a second preferred embodiment, as in the case of a moisturizing serum, the different components are in the following proportions of active ingredient and liposomes:
  • the product of the Clock gene regulates the biological clock through circadian rhythms and metabolism.
  • the protein encodes a transcription factor of the basic helix-loop-helix family (bHLH) and a DNA-binding histone acetyltransferase.
  • the Perl gene is a member of the Period family of genes and is expressed in a circadian pattern in the suprachiasmatic nucleus of the brain, the primary pacemaker of the mammalian brain.
  • the genes of this family encode components that regulate circadian rhythms of locomotor activity, metabolism and behavior. Circadian expression in the suprachiasmatic nucleus continues in constant darkness and a change in the light / dark cycle causes a proportional change in the gene expression in the suprachiasmatic nucleus. The specific function of this gene is not yet known.
  • qPCR quantitative PCR measurement experiment
  • RNA was extracted was extracted, cDNA was synthesized and quantitative PCR (qPCR) was performed in real time.
  • Total RNA extraction was performed using the TRIZOL reagent and subsequently treated with the DNA-free kit.
  • concentration of the RNAs was quantified with the Nano-Drop spectrophotometer and the cDNAs were synthesized from 1 RNA using Random Primers hexamers and Superscrip III reverse transcriptase. By means of RT-PCR it was verified that the cDNA synthesis process had worked properly.
  • the qPCRs were subsequently performed using 1.7 ng of cDNA per reaction, with SYBrGreen Master Mix and 0.25 mM of each pair of direct and reverse oligonucleotides.
  • the PCR conditions were: 40 cycles of denaturation at 95 ° C-15 seconds and banding at 58 ° C-30 seconds, fluorescence reading being taken in this last step.
  • the melting curve was performed by plotting the fluorescence data against temperature (55 ° C to 95 ° C) to verify that there was only one amplification peak. Control sample without cDNA was included to verify the absence of non-specific amplification products.
  • the threshold cycle (Ct) of the internal control (Actin) was subtracted from the threshold amplification value of the study gene cycle (Ct; Perl or ClockEst).
  • the mathematical method Pfaffl was used to calculate the relation of the relative gene expression related to the value of Actin (internal control).
  • the qPCR reactions were performed in triplicate for each experiment.
  • the Telomerase (Tert) gene encodes a ribonucleoprotein polymerase that maintains the length of telomeres by adding the TTAGGG telomeric repeat.
  • the enzyme consists of a protein component with reverse transcriptase activity, encoded by the Tert gene, and an RNA component that acts as a template for telomeric repeat. Telomeres are essential to keep the ends of the chromosomes intact and prevent their degradation.
  • Telomerase maintains the length of telomeres in the cells in which it is expressed (mainly in embryonic cells, stem cells and gonadal cells) and prevents their shortening, which would cause progressive degradation of DNA and cellular aging. Telomerase expression plays a key role in cellular senescence, since it is normally inhibited in postnatal somatic cells, resulting in a progressive shortening of telomeres. Studies in the mouse suggest that telomerase also participates in chromosomal repair, since de novo synthesis of telomeric repeats could occur in the breaks of two strands of DNA.
  • the Cbx5 / HP1 gene (Chromobox homolog 5) encodes a highly conserved non-histone protein that is a member of the heterochromatin protein family.
  • the Cbx5 protein has a single Chromo domain at the Nterminal end that can bind to histone proteins through methylated lysine residues and a "shadow" chromo domain (Chromo shadow domain, CSD) that is responsible for homodimerization and interaction with a number of non-histone proteins associated with chromatin.
  • the protein is enriched in heterochromatin and is associated with centromers.
  • Cbx5 is involved in the epigenetic regulation of gene expression and interacts with telomeric sequences to maintain its integrity.
  • the Tert and CBX5 / HP1 genes are involved in maintaining the integrity of cell telomeres and inhibiting cell senescence.
  • the set-up of the pairs of primers was performed for each of the medaka genes (Tert and Cbx5 / HP1) whose expression was analyzed in the assay.
  • medaka genes Tet and Cbx5 / HP1
  • the primers were tested by PCR with a temperature gradient in the "annealing" phase to determine the most efficient temperature range of the primers.
  • Three independent experiments of eleutheroembryos treatment with the cream were performed and in each experiment the expression of each gene was determined in triplicate by qPCR, each gene being tested a total of 9 times.
  • RNA extraction was performed using the TRIzol ® reagent and subsequently treated with the DNA-free kit to remove traces of DNA.
  • RNA concentration was quantified with Nano-Drop spectrophotometer and the cDNAs were synthesized from ⁇ g of RNA using Random Primers hexamers and Superscrip III reverse transcriptase. By means of RT-PCR it was verified that the cDNA synthesis process had worked properly.
  • the qPCRs were subsequently performed using 1.7 ng of cDNA per reaction, with SYBrGreen Master Mix and 0.25 mM of each pair of direct and reverse oligonucleotides. The PCR conditions were: 40 cycles of denaturation at 95 ° C-15 seconds and banding at 58 ° C-30 seconds, fluorescence reading being taken in this last step.
  • the melting curve was performed by plotting the fluorescence data against temperature (55 ° C to 95 ° C) to verify that there was only one amplification peak.
  • Control sample without cDNA was included to verify the absence of non-specific amplification products.
  • the threshold cycle (Ct) of the internal control (Actin) was subtracted from the threshold amplification value of the study gene cycle (Ct; Telomerase, CBX5 / HP1).
  • the mathematical method Pfaffl was used to calculate the relation of the relative gene expression related to the value of Actin (internal control).
  • the qPCR reactions were performed in triplicate for each experiment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un produit à propriétés contre le vieillissement de la peau, renfermant comme principes actifs principaux avec la téprénone, du tripeptide-32 et du L-glutamyl-amidoéthyl-imidazol ainsi que d'autres principes actifs, tels que l'acide hyaluronique, l'adénosine, la phytosphingonine, un lysat de bifidobactéries et un palmitate d'ascorbyle ou de rétinol, certains d'entre eux étant liposomés.
PCT/ES2014/070068 2014-01-31 2014-01-31 Produit cosmétique à propriétés contre le vieillissement de la peau WO2015114176A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/ES2014/070068 WO2015114176A1 (fr) 2014-01-31 2014-01-31 Produit cosmétique à propriétés contre le vieillissement de la peau

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2014/070068 WO2015114176A1 (fr) 2014-01-31 2014-01-31 Produit cosmétique à propriétés contre le vieillissement de la peau

Publications (1)

Publication Number Publication Date
WO2015114176A1 true WO2015114176A1 (fr) 2015-08-06

Family

ID=53756251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2014/070068 WO2015114176A1 (fr) 2014-01-31 2014-01-31 Produit cosmétique à propriétés contre le vieillissement de la peau

Country Status (1)

Country Link
WO (1) WO2015114176A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021057380A1 (fr) * 2019-09-26 2021-04-01 湖南御家化妆品制造有限公司 Composition et son application dans la préparation de produits de soin de la peau pour réguler le rythme biologique de la peau

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012581A1 (fr) * 1993-11-05 1995-05-11 Exsymol Societe Anonyme Monegasque Produit pseudodipeptide possedant un groupement imidazole et applications
WO2006120646A1 (fr) * 2005-05-13 2006-11-16 Sederma Utilisation topique de teprenone
WO2010091327A2 (fr) * 2009-02-09 2010-08-12 Elc Management Llc Procédé et compositions de traitement de la peau

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012581A1 (fr) * 1993-11-05 1995-05-11 Exsymol Societe Anonyme Monegasque Produit pseudodipeptide possedant un groupement imidazole et applications
WO2006120646A1 (fr) * 2005-05-13 2006-11-16 Sederma Utilisation topique de teprenone
WO2010091327A2 (fr) * 2009-02-09 2010-08-12 Elc Management Llc Procédé et compositions de traitement de la peau

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SESDERMA.: "Producto Sesgen 32.", 3 November 2013 (2013-11-03), Retrieved from the Internet <URL:httos:!/web.archive.org/web/2013106211133/http://www.sesderma.es/es/sesqen-32-Ilposomal-serum.html> [retrieved on 20140929] *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021057380A1 (fr) * 2019-09-26 2021-04-01 湖南御家化妆品制造有限公司 Composition et son application dans la préparation de produits de soin de la peau pour réguler le rythme biologique de la peau
TWI751700B (zh) * 2019-09-26 2022-01-01 大陸商湖南御家化妝品製造有限公司 一種組合物及其在製備調節皮膚生物節律的護膚品中的應用
JP2022550136A (ja) * 2019-09-26 2022-11-30 水羊▲化▼▲妝▼品制造有限公司 組成物、及び皮膚の生体リズムを調節するためのスキンケア製品の製造におけるその使用
JP7245960B2 (ja) 2019-09-26 2023-03-24 水羊▲化▼▲妝▼品制造有限公司 組成物、及び皮膚の生体リズムを調節するためのスキンケア製品の製造におけるその使用

Similar Documents

Publication Publication Date Title
JP5716243B2 (ja) 保湿効果又は老化防止効果を有する少なくとも２つの浸透圧調節物質を含有する化粧品組成物
ES2620406T3 (es) Firma de microARN de la diferenciación epidérmica y sus usos
Yin et al. Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia–reperfusion in mice
ES2859608T3 (es) Hidrolizado de pichia minuta
ES2645011T3 (es) Modulación de dineína en la piel
Kim et al. Poly (γ-glutamic acid)/chitosan hydrogel nanoparticles for effective preservation and delivery of fermented herbal extract for enlarging hair bulb and enhancing hair growth
JP2017530116A (ja) スキンケア組成物の製造方法
ES2936724T3 (es) Composición cosmética o dermatológica que comprende un extracto de Jania rubens y un aceite esencial de helicriso y su uso
BR112015007102A2 (pt) composição de lipídios vegetais para a modulação de funções de matérias queratínicas, método para modulação das referidas funções e uso dos referidos lipídios vegetais
TW201323005A (zh) 皮膚之胸腺素β－４之調節
US11241469B2 (en) Active ingredient obtained from Calendula officinalis and use in the prevention and treatment of cutaneous manifestations due to an imbalance in the epigenome in skin cells
US9303261B2 (en) Composition for controlling chromogenesis including microRNA
CN106132396B (zh) 卤虫提取物用于保护皮肤免受热应力的美容用途
ES2622114T3 (es) Sustancia para restablecer una coexpresión y una interacción normales entre las proteínas LOX y NRAGE
WO2015114176A1 (fr) Produit cosmétique à propriétés contre le vieillissement de la peau
Yang et al. The effect of Q-switched 1064-nm dymium-doped yttrium aluminum garnet laser on the skin barrier and collagen synthesis through miR-24-3p
Foti et al. Sodium dehydroacetate: an emerging allergen
LODéN et al. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics
US20100098732A1 (en) Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or aging skin, and/or hair loss
EP3075373B1 (fr) Produit cosmétique ayant des propriétés réparatrices de l&#39;adn
AR112771A1 (es) Método para evaluar la hidratación bioactiva de un ingrediente o de una mezcla de ingredientes, composiciones cosméticas para la modulación de genes responsables de la hidratación bioactiva de la piel y método para la modulación de la expresión de genes responsables de la hidratación bioactiva de la piel
TW202038903A (zh) 複方精油組合物用於調控ｍｍｐ基因、ｍｃ１ｒ基因、ｋｒｔ基因、ｔｅｒｔ基因、ｔｅｒｃ基因、及／或ｏｇｇ１基因表現量的用途
WO2023180600A1 (fr) Composition d&#39;extraits végétaux pour pallier les effets du vieillissement par la prévention ou le retardement de la sénescence cellulaire
Chalisova et al. Effects of combinations of amino acids on cell proliferation in tissue culture of old rats
Mishina et al. Modification of secondary head-forming activity of microinjected∆ β-catenin mRNA by co-injected spermine and spermidine in Xenopus early embryos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14881055

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14881055

Country of ref document: EP

Kind code of ref document: A1